About StandardX
StandardX is engineering a compact, high-power particle-accelerator platform intended to produce multiple isotopes from a standardized installation. Founded in 2025, it is initially focused on supply for cancer diagnostics and treatment, research and future fusion systems.
What StandardX offers
StandardX is developing a scalable production platform for rare isotopes used in medicine, industry and energy. Its compact particle-accelerator architecture is intended to produce a versatile portfolio including diagnostic and therapeutic medical isotopes, industrial isotopes and tritium for fusion energy.
What sets StandardX apart
StandardX is building a repeatable isotope-production platform rather than a facility dedicated to a single isotope. The compact accelerator architecture is designed to translate specialised nuclear physics into distributed, scalable production for materials that are currently scarce or constrained by centralised supply.